An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of PA-111 Compared to PA-111A in Healthy Adult Volunteers Under Fed State Conditions
Latest Information Update: 25 Apr 2025
At a glance
- Drugs PA 111 (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Addpharma
Most Recent Events
- 25 Apr 2025 New trial record